智通财经APP讯，巨子生物(02367)发布公告，该公司于2025年12月30日斥资1344.08万港元回购40万股 股份，每股回购价格为33.48-33.76港元。 ...

巨子生物(02367)发布公告，该公司于2025年12月30日斥资1344.08万港元回购40万股股份，每股回购价 格为33.48-33.76港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 巨子生物控股有限公司 呈交日期： 2025年12月30日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02367 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 目 ...

每经AI快讯，巨子生物(02367.HK)午后跌超3%，截至发稿，跌2.95%，报33.54港元，成交额2.46亿港 元。 ...

该行指，巨子生物的投资逻辑已由增长转向战略调整，该行认为当前尚缺乏明显的反弹催化剂。在企稳 迹象更加明朗之前，持观望态度。该行将2025-27年收入预测平均下调30%，以反映管理层最新指引及 该行对2026年更加审慎的展望。该行将销售费用率预测从36%上调至38%，以反映调整阶段下的执行挑 战。目标价基于由原来的2026年预测市盈率21.5倍降至16倍。 招商证券国际发布研报称，将巨子生物评级由"增持"下调至"中性"，将目标价从64港元下调45%至35港 元。报告指，公司正面临诸多挑战，包括一系列声誉危机，以及核心品牌可复美在双11大促期间出现两 位数下滑。虽然该行认为公司股价已基本消化相关问题及随后下调2025年销售指引，但该行对2026年前 景仍持谨慎态度。该行认为，当前市场一致预期可能过于乐观。 巨子生物(02367)午后跌超3%，截至发稿，跌2.95%，报33.54港元，成交额2.46亿港元。 ...

智通财经APP获悉，巨子生物(02367)午后跌超3%，截至发稿，跌2.95%，报33.54港元，成交额2.46亿港 元。 该行指，巨子生物的投资逻辑已由增长转向战略调整，该行认为当前尚缺乏明显的反弹催化剂。在企稳 迹象更加明朗之前，持观望态度。该行将2025-27年收入预测平均下调30%，以反映管理层最新指引及 该行对2026年更加审慎的展望。该行将销售费用率预测从36%上调至38%，以反映调整阶段下的执行挑 战。目标价基于由原来的2026年预测市盈率21.5倍降至16倍。 招商证券国际发布研报称，将巨子生物评级由"增持"下调至"中性"，将目标价从64港元下调45%至35港 元。报告指，公司正面临诸多挑战，包括一系列声誉危机，以及核心品牌可复美在双11大促期间出现两 位数下滑。虽然该行认为公司股价已基本消化相关问题及随后下调2025年销售指引，但该行对2026年前 景仍持谨慎态度。该行认为，当前市场一致预期可能过于乐观。 ...

Summary of Key Points Core Viewpoint - On December 29, 55 Hong Kong-listed companies conducted share buybacks, totaling 37.9 million shares and an aggregate amount of HKD 999 million [1][2]. Group 1: Major Companies Involved in Buybacks - Tencent Holdings repurchased 1.057 million shares for HKD 636 million, with a yearly total buyback amount of HKD 78.765 billion [1][2]. - Xiaomi Group-W bought back 3.9 million shares for HKD 151 million, with a total buyback amount of HKD 6.136 billion for the year [1][2]. - China COSCO Shipping Holdings repurchased 3.46 million shares for HKD 47.9 million, with a total buyback amount of HKD 6.866 billion for the year [1][2]. Group 2: Buyback Statistics - The highest buyback amount on December 29 was from Tencent Holdings at HKD 636 million, followed by Xiaomi Group-W at HKD 151 million [1][2]. - The largest number of shares repurchased on December 29 was by Four Seasons Medicine, with 8 million shares, followed by Xiaomi Group-W and China COSCO Shipping Holdings with 3.9 million and 3.46 million shares, respectively [1][2]. Group 3: Additional Companies and Their Buyback Data - Kingsoft repurchased 713,600 shares for HKD 20 million, with a total buyback amount of HKD 33.465 million for the year [2]. - Kuaishou-W bought back 310,000 shares for HKD 20 million, with a total buyback amount of HKD 306.840 million for the year [2]. - Other notable companies include Miniso Group, which repurchased 320,600 shares for HKD 1.195 million, and Four Seasons Medicine, which had a total buyback amount of HKD 15.332 million for the year [2][3].

格隆汇勾股大数据显示，腾讯控股(00700)、小米集团-W(01810)、三花智控(02050)、中远海控(01919)、 金山软件(03888)、快手-W(01024)、巨子生物(02367)、碧桂园服务(06098)、名创优品(09896)、四环医 药(00460)、明源云(00909)、津上机床中国(01651)、多点数智(02586)、科济药业-B(02171)、富智康集团 (02038)、趣致集团(00917)、汇通达网络(09878)、海吉亚医疗(06078)、心玮医疗-B(06609)、德康农牧 (02419)、绿城服务(02869)、捷利交易宝(08017)、歌礼制药-B(01672)、VITASOY INT'L(00345)、同道猎 聘(06100)、海尔智家(06690)、荃信生物-B(02509)、知行科技(01274)、连连数字(02598)、昊海生物科技 (06826)、锅圈(02517)、叮当健康(09886)、天伦燃气(01600)、中远海发(02866)、信利国际(00732)、绿茶 集团(06831)、思派健康(00314)、希玛医疗(03309)、枫叶教育(01317)、北 ...

证券时报·数据宝统计，巨子生物在港交所公告显示，12月29日以每股34.280港元至34.760港元的价格回 购40.00万股，回购金额达1381.44万港元。该股当日收盘价34.560港元，下跌3.03%，全天成交额4.01亿 港元。 今年以来该股累计进行12次回购，合计回购480.00万股，累计回购金额1.69亿港元。（数据宝） 巨子生物回购明细 | 日期 | 回购股数（万股） | 回购最高价（港元） | 回购最低价（港元） | 回购金额（万港元） | | --- | --- | --- | --- | --- | | 2025.12.29 | 40.00 | 34.760 | 34.280 | 1381.44 | | 2025.12.23 | 40.00 | 36.480 | 35.740 | 1439.66 | | 2025.12.22 | 40.00 | 36.340 | 35.860 | 1442.97 | | 2025.12.19 | 40.00 | 35.520 | 34.540 | 1405.36 | | 2025.12.18 | 40.00 | 35.040 | 34.420 | 1388 ...

Core Viewpoint - The strategic partnership between Giant Bio and Nordberg Medical aims to leverage Giant Bio's patented recombinant collagen technology for global market expansion in the medical aesthetics sector, indicating a shift towards international growth opportunities [2][5][10]. Financial Performance - In the first half of the year, Giant Bio reported revenue of 31.13 billion yuan, a year-on-year increase of 22.52%, and a net profit attributable to shareholders of 11.82 billion yuan, up 20.23% [7]. - Despite positive growth, the revenue and net profit growth rates have slowed compared to previous years, where growth rates exceeded 40% [7]. - The company's gross margin for the first half of the year was 81.68%, down from previous years' figures of 85.11%, 84.14%, and 82.4% [7]. Strategic Developments - The partnership with Nordberg Medical allows Giant Bio to utilize the latter's established global marketing and sales network, facilitating quicker entry into international markets [5][10]. - Giant Bio received a medical device registration certificate for its recombinant type I α1 collagen product, marking a significant step into the professional medical sector [10][12]. Market Position and Competition - The competitive landscape in the recombinant collagen market is intensifying, with companies like Huaxi Bio and Jinbo Bio also making significant advancements [10][11]. - Jinbo Bio has established a lead in the market with multiple approved medical device registrations, highlighting Giant Bio's relatively slower progress in this area [11][12]. Stock Performance and Market Sentiment - Giant Bio's stock has seen a significant decline, dropping approximately 60% from its peak of 85.14 HKD per share earlier in the year, now trading at 34.56 HKD [12]. - The company announced a share buyback plan to repurchase up to 10% of its issued shares, reflecting confidence in its long-term strategy and growth potential [12].